Online OCS PDF Braindumps are best from killexams.com

Proceed through our OCS Questions and Answers plus you may really feel confident regarding the OCS check. Pass your OCS along with high marks or even your money back again. Everything you require to pass the particular OCS is provided right here. We have aggregated a database associated with OCS PDF Braindumps obtained from real examinations to provide you with a get prepared and pass OCS upon the very very first attempt. Simply established up OCS test prep Exam Sim and Practice Test. You will complete the OCS exam.

Exam Code: OCS Practice test 2022 by Killexams.com team
Ophthalmic Coding Specialist
Medical Ophthalmic book
Killexams : Medical Ophthalmic book - BingNews https://killexams.com/pass4sure/exam-detail/OCS Search results Killexams : Medical Ophthalmic book - BingNews https://killexams.com/pass4sure/exam-detail/OCS https://killexams.com/exam_list/Medical Killexams : About the Editors

Editor-in-Chief

Professor Sobha Sivaprasad - Moorfields Eye Hospital and University College London, London, UK

Dr Sivaprasad is a Consultant Ophthalmologist at NIHR Moorfields Biomedical Research Centre, London, UK. She completed her Medical Retina Fellowship from Moorfields Eye Hospital. Her higher research degree from Cranfield University and King's College Hospital is on ‘Co-morbidity of age related macular degeneration and atherosclerosis’.
Dr Sivaprasad has active clinical and laboratory research interests in age related macular degeneration, diabetic retinopathy and retinal vascular disorders. Her research focuses on biomarkers and modeling of retinal morphology in retinal diseases.
She also runs several clinical trials in these areas and has over 100 peer reviewed publications to her credit.

Associate Editors

Tin Aung - Singapore National Eye Centre, Singapore

MBBS (Singapore), FRCS(Ed), FRCOphth (UK), MMed (Ophth) (Singapore), FAM (Singapore), PhD (London)
Professor Aung is currently:
1. Executive Director, Singapore Eye Research Institute;
2. Deputy Medical Director (Research) and Head, Glaucoma Department, Singapore National Eye Centre;
3. Professor, Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore

Professor Aung is a clinician scientist, with clinical practice focusing on glaucoma and research interests in angle closure glaucoma and glaucoma genetics. With >450 publications, Professor Aung has been awarded >US$20 million in competitive research grant funding. He has received numerous awards including the Singapore Translational Research (STaR) Investigator Award in 2014, the Singapore National Medical Research Council-Clinician Scientist Awards in 2005 and 2008, the President's Science Award in 2009, the Nakajima (2007) and De Campo Awards (2013) from the Asia Pacific Academy of Ophthalmology and the Alcon Research Institute Award in 2013.
Professor Aung is a member of the Editorial Boards of Ophthalmology, Journal of Glaucoma, Eye, Graefe's Archive for Clinical and Experimental Ophthalmology, and 6 other journals. He is currently President of the World Glaucoma Association and also serves as a Board member of the Asia-Pacific Glaucoma Society and the Asian Angle Closure Glaucoma Club.

Rupert Bourne - Cambridge Eye Research Centre, Cambridge University Hospital, Cambridge, UK

Rupert Bourne is Professor of Ophthalmology at Anglia Ruskin University, Cambridge and Consultant Ophthalmic Surgeon at Cambridge University Hospital, where he directs the Cambridge Eye Research Centre. He trained at Moorfields Eye Hospital and undertook two Glaucoma fellowships, one there and another at the Shiley Eye Centre/Hamilton Glaucoma Center in San Diego, California. He has a strong research interest, particularly in advanced techniques of Glaucoma diagnosis and progression and the management of Glaucoma in the community, along with overseas ophthalmology which has involved design and analysis of several large population-based surveys of eye disease, several national in scope, eg. Pakistan, Bangladesh and Trinidad. He is the Chair of the National Institute for Health Research Ophthalmology Specialty Group, responsible for NHS research delivery. In his role as Coordinator of the Vision Loss Expert Group of the Global Burden of Disease Study, he has overseen the long-term research into the world-wide prevalence rates of blindness and visual impairment, in partnership with the World Health Organization. He is Chief Investigator for the UK National Eye Health and Hearing Study due to start in 2020.

Christopher Brand - Royal Hallamshire Hospital, Sheffield, UK

Parwez Hossain - Southampton University, Southampton, UK

Parwez Hossain is King James IV Professor of Surgery (Royal College of Surgeons, Edinburgh) and Associate Professor in Ophthalmology at the University of Southampton. He qualified in Medicine from Aberdeen University and trained in Ophthalmology in Aberdeen, Nottingham, Leicester & Bascom Palmer Eye Institute, Miami, USA. He sub-specializes in Cornea & External Eye Disease, and is head of the corneal service for the Southampton Eye Unit, Southampton University Hospital NHS Foundation Trust, takes care of a diverse range of corneal diseases with patients coming from different regions of the UK.

Parwez's clinician-scientist career started as Wellcome Trust Fellow at Aberdeen University where he studied the mechanisms of lymphocyte traffic in ocular inflammation. In his PhD thesis, he established a novel method for in vivo tracking of immune cells in the posterior segment of the eye. The technique allowed the observation of lymphocytes and inflamed vascular endothelium, in real-time. Following his PhD, Parwez moved to Nottingham University, where, as a Clinical Lecturer, his interest focused on investigating the innate immune mechanisms in corneal inflammation. He determined that the immune adhesion molecule CD34 is a unique marker for human corneal stromal keratocytes (corneal fibroblast) activation. Whilst at Nottingham, he also helped to establish the effectiveness of a new surgical technique called 'Fine Needle Diathermy' to treat long standing corneal vascularization. This treatment helps against chronic corneal vascularization and can restore vision in patients with vascularisation from herpes keratitis or chronic corneal graft rejection. Parwez also developed techniques in corneal confocal imaging and his work has highlighted the benefit of this in the early detection of diabetic peripheral neuropathy (published in The Lancet).

After his fellowship training period, Parwez moved to Southampton, to start a research programme in corneal infection. In his current role, he leads a corneal infection research group comprising a post-doctoral fellow, PhD & undergraduate research students. His research focus is to develop new diagnostic techniques for the rapid diagnosis and monitoring of corneal infections. His group have developed technologies such as anterior segment OCT & microfluidic impedance cytometry to allow rapid microbial diagnostic detection/monitoring. With collaboration with his surgical colleagues in Southampton, Parwez has developed an active surgical research programme with the aim to develop optimal surgical methods for corneal diseases. Developing method such as ultrathin DSEK and accelerated protocols for collagen cross-linking for Keratoconus. His surgical team are part of the UK Collagen Cross-linking Consortium and are major providers for collagen crosslinking therapy for the South Coast of the UK. In 2018, Parwez was awarded King James IV Professor in Surgery by The Royal College of Surgeons, Edinburgh for his sustained research in the development of real-time diagnostic methods/devices in Ophthalmology.

His work has been supported by research grants from the Royal College of Surgeons of Edinburgh, the British Council for the Prevention for Blindness, National Eye Research Centre, Engineering & Physicals Sciences Research Council (UK) and Medical Research Council (UK).

Anthony Khawaja - Moorfields Eye Hospital NHS Foundation Trust, London, UK

Anthony Khawaja is Associate Professor at the UCL Institute of Ophthalmology and Honorary Consultant Ophthalmic Surgeon at Moorfields Eye Hospital, London. He is currently a UK Research & Innovation Future Leaders Fellow. Anthony completed his medical training at the University of Cambridge and University College London and has undertaken the majority of his ophthalmic residency training at Moorfields Eye Hospital. His research training began with a Wellcome Trust funded PhD programme at the University of Cambridge, including a Masters in Epidemiology for which he won the Nick Day Prize. He was also awarded the Berkeley Fellowship which supported a research period at Harvard Medical School.

Anthony’s research interests concern the genetic and environmental epidemiology of glaucoma, and learning about disease pathogenesis and optimal care pathways by probing routinely collected data. His ultimate aim is to develop clinical tools to personalise screening and treatment of glaucoma. Anthony is an active member of international multidisciplinary consortia for eye diseases, including the International Glaucoma Genetics Consortium and the European Eye Epidemiology consortium. Anthony established the Young Ophthalmologists section of the European Society of Ophthalmology and is director for the European Leadership Development Programme. He was recently voted in The Ophthalmologist's top 100 most influential thought leaders in ophthalmology globally. Anthony is chair of the Royal College of Ophthalmologists Informatics sub-committee.

Timothy Y Y Lai - The Chinese University of Hong Kong, Hong Kong, China

Dr Lai is an Honorary Clinical Associate Professor of the Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, and Director of 2010 Retina and Macula Centre, Hong Kong. His clinical and research interests lie in the medical and surgical management of retinal diseases, particularly polypoidal choroidal vasculopathy, choroidal neovascularization, central serous chorioretinopathy, myopic maculopathy, diabetic retinopathy; visual electrophysiology; and genetics of retinal diseases and uveitis. He has extensive experience in the conduct of clinical trials and is the principle investigator of over 15 industry-sponsored Phase II, III and IV clinical trials.

As one of the leading experts in vitreo-retinal diseases in the Asia-Pacific region, Dr Lai has published more than 180 papers in international peer-reviewed journals and co-authored and edited 10 textbooks. He has also delivered over 120 invited lectures worldwide and has received a number of 

Andrew Lee - Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA

Andrew G Lee, M.D. is an honors graduate of the University of Virginia undergraduate school and an Alpha Omega Alpha graduate of the UVA School of Medicine. He completed his ophthalmology residency and was the chief resident at Baylor College of Medicine in Houston, Texas in 1993. Following eye residency, Dr Lee completed a clinical fellowship in neuro-ophthalmology with Neil R. Miller MD at the Wilmer Eye Institute and was a post-doctoral Fight for Sight research fellow at the Johns Hopkins Hospital in Baltimore, Maryland from 1993-1994. He was an Associate Professor at Baylor College of Medicine and Adjunct Associate Professor at the M.D. Anderson Cancer Center in Houston from 1994-2000. From 2000-2008, Dr Lee was Professor of Ophthalmology, Neurology, and Neurosurgery in the H. Stanley Thompson Neuro-ophthalmology Clinic at the University of Iowa Hospitals and Clinics. In April 2009 Dr Lee assumed the chairmanship of ophthalmology at The Blanton Eye Institute, at Houston Methodist Hospital in Texas and was appointed Professor of Ophthalmology, Neurological Surgery and Neurology at Weill Cornell Medical College.
Dr Lee has published over 260 peer-reviewed articles, 40 book chapters, and three full textbooks in ophthalmology. He serves on the Editorial Board of 12 journals including the American Journal of Ophthalmology, the Canadian Journal of Ophthalmology, and Eye. He has received the American Academy of Ophthalmology (AAO) Honor Award, the AAO Secretariat Award, and the AAO Senior Achievement Award. Dr Lee has been the invited guest speaker at over 140 national and international eye meetings.
Dr Lee’s area of research interest is in optic nerve disease. He was the Director of New Educational Initiatives in the Graduate Medical Education (GME) office at Iowa and has published extensively in the area of resident graduate medical education. In April 2009 Dr Lee assumed the chairmanship of ophthalmology at The Methodist Hospital in Houston, Texas and was appointed Professor of Ophthalmology, Neurological Surgery and Neurology at Weill Cornell Medical College.

Caroline J MacEwen - Ninewells University Hospital, Dundee, UK

Caroline (Carrie) MacEwen is a Consultant Ophthalmologist at Ninewells Hospital and Medical School and Head of the Ophthalmology Department at the University of Dundee (Honorary Professor). She trained in Glasgow, Dundee and London. Her clinical interests lie in the field of strabismus and ocular motility after carrying out her subspecialty training at Moorfields Eye Hospital under the guidance of John Lee. Research interests include paediatric naso -lacrimal disease, trauma, sports medicine, epidemiology and clinical research on strabismus management. She has been a member of the British Ophthalmic Surveillance Unit (BOSU) committee since its inception. International and national awards for her work include the Gregg medal for ‘contribution to medical science’, the Founder's Cup, Ian Fraser trophy, Spencer Walker prize and Foulds' trophy. She has published more than 150 papers, written or edited 3 textbooks and written 17 book chapters. Carrie is an associate postgraduate Dean in the East of Scotland.
She is Chair of the Academy of Medical Royal Colleges (2017–2020) and was President of the Royal College of Ophthalmologists (2014 – 2017). She represented the RCOphth in the development of the Faculty of Sport and Exercise Medicine (FSEM)
She is ophthalmology clinical co-lead for the Getting It Right First Time (GIRFT) project, was a member of the Right Care Clinical Improvement Group and chaired the Elective Care Transformation Ophthalmology Working Group.
She is Ophthalmology Specialty Adviser to the Scottish Government and leads the National Ophthalmology Workstream in Scotland and is a member of the National Access Collaborative. Professor MacEwen chaired the Scottish update of Certification of Vision Impairment and was a member of the UKCVI development board, the UK Vision Strategy Leadership Group and Transition Programme Board.
Carrie has worked nationally with all eye health care professionals to share and develop new ways of delivering ophthalmic care and has delivered a framework to support this.  She has been made an honorary fellow of the College of Optometrists and the British and Irish Orthoptic Society, the Faculty of Sport and Exercise Medicine and the Royal College of Physicians, Edinburgh

Hunter MacLean - Queen Alexandra Hospital, Portsmouth, UK

Hunter Maclean is a Consultant Ophthalmologist at the Queen Alexandra Eye Hospital Portsmouth, in the south of England. He specialises in oculoplastics and lacrimal surgery. He received his medical degree from Edinburgh University and did further training there and at Newcastle with a fellowship in Sydney, Australia before taking up his consultant post in 1998. He was a founding member of the British Oculoplastic surgical society and takes an active part in research within the department and is also the current President of the Southern Ophthalmological Society. He has written one book and contributed several chapters in others. He was appointed Associate Editor of Eye in 2009.

Saaeha Rauz - University of Birmingham, Birmingham and Midland Eye Centre, Birmingham, UK

Dr Rauz is a clinical academic who has a specialist interest in complex, blinding immune-mediated ocular surface diseases at the University of Birmingham (UK) and the Birmingham & Midland Eye Centre, Birmingham (UK). She has an expertise in rare progressive conjunctival scarring disorders such as mucous membrane pemphigoid and Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis together with secondary causes of inflammatory dry eye disease including Primary Sjögren’s Syndrome and Atopic Keratoconjunctivitis.
A Bedside-to-Bench-to-Bedside approach underpins her research portfolio, with patients pivotal for informing research directions. Key areas of research include (i) evaluating drivers of ocular surface inflammation and scarring, (ii) monitoring and measuring outcomes and (iii) translating technologies that modify biological processes.
The ultimate aim of her clinical and research portfolio is to Boost disabling signs and symptoms that impact upon patient wellbeing and quality of life.

Federico Ricci - University of Rome Tor Vergata, Rome, Italy

Federico Ricci is Associate Professor in Ophthalmology at the University of Tor Vergata of Rome (Italy), Department of Experimental Medicine. He received his Medicine degree from University la Sapienza of Rome and trained in Ophthalmology from the same University. He is the past president of Italian Retina Society and is an active member of the Italian Ophthalmological Society executive board. He is a member of CNIT (National Inter-University Consortium for Telecommunications) and is involved in projects of telemedicine and AI applications in Ophthalmology. Since 2006 he has been an “expert consultant” for AIFA (Italian Medicines Agency). Professor Ricci is the Director of "Retina Diseases Unit" at PTV Foundation Hospital of Rome. The Unit is a Regional Referral Centre and Clinical Trial Centre for AMD and blinding retinal diseases. His basic science and clinical and research interests are focused on angiogenesis in eye diseases and on management of degenerative and inherited retinal diseases. He has extensive experience in registration clinical trials and, since 2008, has been the principal investigator of over 40 trials.

David Steel - Sunderland Eye Infirmary, Sunderland, UK

David Steel is a Consultant Ophthalmologist and Vitreo-retinal surgeon at Sunderland Eye Infirmary and Honorary Senior Lecturer at the Institute of Genetic Medicine at Newcastle University, in the North East of England. He graduated in Medicine at Newcastle in 1989 and completed his initial training posts at Sunderland and Newcastle before registrar posts at Bristol, Torbay and Bath. He undertook sub specialty training in retinal surgery at the Royal Victorian Eye and Ear Hospital, Melbourne and was appointed Consultant at Sunderland in 1999. David leads the medical and surgical retinal service at the Eye Infirmary and the units expanding clinical trials unit. He has research interest in many aspects of retinal disease and was co-founder of the Newcastle University retinal stem cell group (http://www.retinalstemcellresearch.co.uk). He has published approximately 140 peer reviewed publications with ~2900 citations, and was named as the NIHR and Royal College of Ophthalmologists Researcher of the year in 2018. He is an associate Editor for the Journal Eye, and on the editorial board of Graefe's Archive for Clinical and Experimental Ophthalmology and the ASRS’s Journal of Vitreo-Retinal Diseases. He has been a board member of the British and Eire Association of Vitreoretinal Surgeons since 2009 and the British Ophthalmic surveillance unit since 2014. He is an elected member of the British Eye Study group and the Club Jules Gonin, and has been an invited Guest speaker at several National and International retinal societies.  

Rupal H Trivedi - Storm Eye Institute, Charleston, USA

Dr Trivedi is a Research Associate Professor at Storm Eye Institute, Medical University of South Carolina, USA. She completed her residency in Ophthalmology from India in 1995. From 1995 to 2000, she worked at Iladevi cataract and IOL research center, India. She received her Master of Science in Clinical Research (MSCR) degree from Medical University of South Carolina. Dr Trivedi's research interests include cataract surgery, especially for children. She has published more than 100 articles in peer-reviewed journals and presented her research work at various national and international meetings. She is recipient of various awards including ASCRS foundation Binkhorst young ophthalmologist award, American Academy of Ophthalmology Achievement Award, RCMAR scholar award and Clinical Research Curriculum Award. 

Editorial Office Coordinator

Steve Beet, UK

Sat, 13 Nov 2021 11:58:00 -0600 en text/html https://www.nature.com/eye/editors
Killexams : Ophthalmic Plastic & Cosmetic Surgery, Inc. & Aesthetic Medispa of West County

Drs. John Holds, Adam Buchanan, and Sara Reggie have more than 50 years of combined experience in ophthalmic plastic surgery. They specialize in cosmetic and reconstructive and eyelid surgery, including treatment of eyelid malposition and defects after cancer surgery, medical and cosmetic blepharoplasty (eyelid lift), ptosis repair (droopy eyelid), and brow lift. The practice also provides medical and cosmetic Botox, dermal filler treatments in the eye area and face, and laser skin resurfacing. The team approaches each patient’s concerns and treatment plan with the goal of enhancing one’s natural beauty and achieving natural-looking results.

Dr. Holds is board-certified and fellowship trained as an ophthalmic plastic surgeon. With more than 35 years of experience, Dr. Holds has extensive experience in performing surgery and training surgeons for the prestigious American Society of Ophthalmic Plastic and Reconstructive Surgery, of which there are less than 500 fellows nationwide. Dr. Holds is the author of numerous peer-reviewed publications and books, and he is frequently invited to lecture at national and international meetings.

Dr. Buchanan joined the practice in July 2018 and is also a fellowship trained member of the American Society of Ophthalmic Plastic and Reconstructive Surgery. Prior to joining the practice, he served in the Army where he was ophthalmic plastic faculty involved in resident education at Madigan Army Medical Center in Fort Lewis, Washington. Dr. Buchanan sees patients at the Des Peres and St. Peters locations.

Dr. Sara Reggie was welcomed to the practice in 2020. She is also a board-certified ophthalmologist and a fellow in the American Society of Ophthalmic Plastic and Reconstructive Surgery. She adds a refreshing perspective on ophthalmic plastic surgery to the practice and sees patients at all office locations.

In addition to their St. Peters and St. Louis offices, OPCS will be opening an all new location in Arnold later this year.


12990 Manchester Road Stes. 101 & 102, Des Peres, MO

300 St. Peters Centre Boulevard, St. Peters, MO

Coming Soon: 3530 Jeffco Boulevard, Ste. 100, Arnold, MO

Tue, 12 Jul 2022 01:51:00 -0500 en-us text/html https://www.stlmag.com/locations/ophthalmic-plastic-cosmetic-surgery-inc-aesthetic-medispa/
Killexams : VIDEO: Experts discuss social media, web presence for ophthalmic practices, part 2

July 31, 2022

1 min watch

Save

Source:

Healio Interviews

Disclosures: Evans reports being the founder and CEO of Ceatus Media Group. Matossian reports no relevant financial disclosures.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this Healio Video Perspective, Cynthia A. Matossian, MD, FACS, and David Evans, PhD, MBA, discuss three tips for creating effective social media posts.

“People want to share three things: posts that inform, posts that inspire or posts that entertain,” Evans said. “If you think about the multiplication numbers, if you have one patient or prospective patient that has 300 followers and they share your post with their 300 followers, that’s 90,000 people that are touched by the information you are sharing.”

Sun, 31 Jul 2022 03:16:00 -0500 en text/html https://www.healio.com/news/ophthalmology/20220729/video-experts-discuss-social-media-web-presence-for-ophthalmic-practices-part-2
Killexams : What do YOUR eyes say about your health? Expert reveals how poor diet and bad circulation can cause issues such as dark circles and dryness (and how to fix them)

What do YOUR eyes say about your health? Expert reveals how poor diet and bad circulation can cause issues such as dark circles and dryness (and how to fix them)

  • London-based Consultant Ophthalmic and Oculoplastic surgeon Dr Elizabeth Hawkes has revealed common eye conditions and what causes them
  • She reveals top tips to treat them, from reducing salt intake to using cold tools 
  • Dark circles can be caused by genetics, allergies or dehydration
  • Forgetting facial SPF can lead to crow's feet around the eyes  

The eyes are the first part of the face to show signs of ageing, and after two stressful years  and many hours spent on Zoom, many peple are noticing the impact on their ocular health.  

But if you're struggling with dark circles, puffy or dry eyes, or crow's feet, it might be useful to know what’s causing your specific eye issue and what you can do to treat it.

Eye expert, Dr Elizabeth Hawkes, who is a Consultant Ophthalmic and Oculoplastic surgeon based in West London, is eager to emphasise the importance of maintaining eye health.

‘It’s wrong to assume that visiting an eye specialist is something that you only do when you’ve got something wrong with your eyes, because maintaining regular check-ups is vital,’ she says. ‘Your eyes reveal a great deal about your overall health and through a thorough examination problems can be identified early in order to get treatment quickly.’

Here Femail reveals the different issues that can affect your eyes and Dr Hawkes’ advice about what causes them and how to treat them. 

DRY OR WATERY EYES 

People with dry eyes often don’t make enough tears to lubricate their eyes or the ones that are made are of poor quality, as a result the front of the eye dries up too quickly resulting in irritation (stock image)

Dry eye is a common condition affecting one in four people in the UK. It’s more prevalent in women. 

It's estimated that 15 to 33 per cent of people aged 65 years or over have dry eye disease, although this is likely to be much higher because many people with mild symptoms don’t go to the doctor. 

It’s more common during menopause and pregnancy and celebrity sufferers include Jennier Aniston who has previously spoken of her addiction to eye drops as a result.

‘People with dry eyes often don’t make enough tears to lubricate their eyes or the ones that are made are of poor quality, as a result the front of the eye dries up too quickly resulting in irritation,' explained Dr Elizabeth Hawkes. 'This can cause discomfort and also cause the eye to produce watery or excessive tears.'

‘Symptoms of dry eyes include eyes that are itchy, sore, feel gritty, red, blurry, sensitive to light or are more watery than normal.’

What causes it 

‘There are a number of reasons why people might get dry eyes, these are some examples..

Blepharitis is the most common cause of dry eye disease. This is an inflammatory condition where the oil secreting eyelid glands, meibomian glands, become blocked.

The elements - exposure to cold, dry air and wind, as well as central heating which can be extremely drying to the eyes because heating the air evaporates the water in it, creating a dry atmosphere.

Lifestyle factors can exacerbate dry eyes such as long periods working at a computer screen, a lack of sleep, a poor diet lacking in omega-3 and other nutrients that are vital for healthy eyes, as well as smoking and drinking alcohol.

Contact lens wearers are sometimes more prone to dry eyes too, as are people over 50, especially women. This is largely due to the hormone changes that occur for women during pregnancy, when using birth control medication or during the menopause.’

Some medical conditions are linked with dry eye disease.

How to treat 

‘You can treat dry eyes yourself by keeping them clean and taking regular breaks from computer screens,’ advised Dr Elizabeth. 

‘Also making sure you’re not straining your eyes when using a computer. Do this by making sure the screen is at eye level. Humidifiers at home can help to stop the air getting dry.

'If you wear contact lenses it can help to take them out and wear glasses to deliver your eyes a rest occasionally. 

'Getting plenty of sleep is essential too. A pharmacist may be able to help by advising on possible treatments such as eye drops, gels, or allergy medicines. However if the problem persists it’s advisable to see an eye specialist for a thorough eye examination.’

PUFFY EYES 

Puffy eyes are a common eye complaint. It is caused be a variety of factors such as lack of sleep, allergies, nasal congestion and dehydration (stock image)

Puffy eyes are an extremely common eye complaint, especially at this time of year with summer being allergy season.

'Puffy eyes typically present as mild swelling of the upper and lower eyelid,’ explained Dr Elizabeth. ‘They may or may not be accompanied by itchy eyes, watery eyes, and itching of the eyelid skin.

What's the cause?   

'Puffy eyes tend to be caused by a variety of factors such as lack of sleep, allergies, nasal congestion, and dehydration as well as eating too much salt. 

'Festoons, or malar mounds (the medical term for skin folds or swelling in the lower eyelids and upper cheek area) can also be caused by poor lymphatic drainage within the eye area.

Eye infections such as viral conjunctivitis and blepharitis can also cause puffiness and unfortunately cold tools won’t fix this. 

Eyelid infections may be caused by certain bacteria that overgrow on the skin and it’s therefore important to treat the underlying cause to provide relief to the eyelid puffiness.’

How to treat 

If you believe an eye infection is to blame for the swelling, make an appointment to see an eye specialist as soon as possible to receive proper treatment.

Cold tools like ice globes can be very effective and work in a number of ways.  

There are a number of different types of eyes and eye conditions, and each have their own distinct features. Consultant Ophthalmic and Oculoplastic surgeon Dr Elizabeth Hawkes (pictured) explains what they all are and how to treat them 

'Using ice-cold tools gives a cold shock to the skin which then sees our body send more blood to the targeted area,’ explained Dr Elizabeth. ‘More blood essentially means more oxygen and a richer nutrient delivery which in turn helps to flush away toxins that have built up and reduce water retention.

‘Used correctly, they can minimise inflammation and puffiness - especially in the morning - help lymphatic drainage and sinus pressure as well as offering benefits for the skin too by reducing redness and kick starting the circulation to provide a radiant glow to the skin.’

‘I'd generally suggest that people use them for no longer than 15 minutes each morning. Apply them to the skin and very gently roll them underneath the eye from the side of the nose out towards the cheekbone. 

'Follow by cleansing and applying your daily anti-oxidant eye serum and a broad-spectrum SPF.’

Be warned though. While ice globes and cooling tools do have benefits, it’s important not to keep the skin in direct contact with something very cold for too long.

Other treatments include getting more sleep, elevating your pillow slightly and drinking more water. 

DARK CIRCLES  

Dark circles under the eyes could be caused be a variety of factors such as genetics, allergies or dehydration (stock image)

Dark circles under the eyes are traditionally thought of as a sign of tiredness. However, Dr Elizabeth Hawkes reveals that this is not always the case.

‘Eyelid skin is unique to the rest of the body. Importantly there is no subcutaneous fat underneath the skin. The eyelid layers are skin, orbicularis muscle, septum, fat (eyebags). 

How to avoid getting dark cirlces and how to cover them up 

  • Stay hydrated
  • Don’t smoke
  • Wear UV protection such as sunglasses in the day as well as SPF, and use retinol at night
  • Consult a makeup artist and invest in good quality undereye makeup to help camouflage the appearance of dark circles
  • Reduce salt intake which causes puffiness
  • Be careful when removing eye makeup, remember the eyelid skin is very delicate and to remove makeup thoroughly yet carefully
  • Do not rub the eyes excessively
  • Get enough sleep
  • Use a night cream to keep the skin hydrated
Advertisement

'Whereas in the rest of the face there is a subcutaneous layer of fat directly underneath the skin. For this reason eyelid skin is prone to appear darker than the rest of the face.

What's the cause? 

  • Genetics – pigmented skin due to ethnicity because of higher levels of melanin. Family history of dark circles.
  • Vascular - The eyelids are very vascular, due to poor circulation the vessels can become dilated. This will make them more apparent under the eyelid skin and cause appearance of dark circles.
  • Allergies - such as hayfever and eczema can cause hypertrophy and erythema of the eyelid skin which contributes to the appearance.
  • Dehydration and Smoking.
  • Ageing – volume loss and descent of the structures around the eyelid will cause the appearance of the tear trough and also worsen the appearance of dark circles. Over the years, the bone of the orbit atrophies and this causes the eyes to sit further back in the socket and appear sunken. This enhances the appearance of dark circles.'

How to treat:

‘Whilst topical creams can help to address some dark circles, it depends on the cause,’ explains Dr Elizabeth Hawkes. ‘Topical creams are good for dehydration & allergy relief but they will not restore volume. 

'They will not cause the blood vessels under the eyes to constrict, nor will they reverse a family history of dark circles. 

'There is a prescription only treatment that will help reduce the production of melanin in the skin and can be a useful tool in improving the appearance of dark circles, however it has to be used under the guidance of a specialist only.

'It is possible to treat dark circles in-clinic however in order to do this effectively it’s important to visit an oculoplastic specialist who will take a full medical history and perform a thorough examination to ascertain the underlying cause and ultimately determine the correct management,’ explains Dr Elizabeth Hawkes.

‘The treatments vary depending on the cause, and include; topical prescription creams, a chemical peel, dermal filler to restore volume or surgical lower eyelid blepharoplasty may be required as an option for dark circles. 

'A thorough ophthalmic examination is necessary to exclude an eye disease or allergy that could be affecting the skin such as allergic conjunctivitis secondary to pollen. 

'Anti-wrinkle injections to the eye muscle, the orbicularis muscle can play a role too to reduce the appearance of dark circles.'

RED, BURNING OR STICKY EYES  

If you’re experiencing red, burning or sticky eyes you could be suffering from Blepharitis. It is a chronic inflammatory condition of the eyelids (stock image)

If you’re experiencing red, burning or sticky eyes you could be suffering from Blepharitis.

The symptoms of Blepharitis include red eye, burning, sticky eyes, excessive watering, ocular discomfort, light sensitivity and foreign body sensation. 

It can also cause excessive eyelid closure or twitching, ‘blepharospasm’, which sometimes requires regular botulinum toxin injections around the eye and brow region.’

What's the cause?

‘This is a chronic inflammatory condition of the eyelids,secondary to an overgrowth of bacteria on the eyelashes and eyelids,’ explained Dr Elizabeth. 

‘The meibomian glands are situated in the upper and lower eyelids in close proximity to the eyelashes. They secrete lipid which is the outer layer of our tear film and protects the ocular surface.

Many people know about the common menopause symptoms, such as hot sweats, low libido and brain fog, however not many people realise that it can affect your eyes too.

‘The hormone changes that occur during the menopause can result in Blepharitis,’ said Dr Elizabeth.

How to treat 

‘There is unfortunately no cure as such for blepharitis,’ Dr Elizabeth said. ‘And so the mainstay of treatment at all stages is lid hygiene to control the bacterial build-up. 

'Other treatments such as antibiotics, steroids and ocular lubrication may also be necessary for different sequelae of the condition.'

Crow’s Feet

Crow’s Feet is the common name given to wrinkles at the sides of the eyes that stretch out towards the temples, in a similar shape to a crow’s claw (stock image)

Crow’s Feet is the common name given to wrinkles at the sides of the eyes that stretch out towards the temples, in a similar shape to a crow’s claw.

‘The eyes are the first place on the face to show signs of ageing,’ explains Dr Elizabeth Hawkes. 

‘The skin in this area is thinner and more delicate than the skin on the rest of the face and therefore more susceptible to lines and wrinkles. 

What's the cause? 

'Actions such as laughing, squinting, and frowning causes your face to contract and over a prolonged period of time this, alongside the depletion of collagen and elastin as part of the natural ageing process, combined with lifestyle factors such as sun damage and pollution can result in Crow’s Feet forming.’

How to treat

‘People often apply sunscreen to their face but forget to protect the delicate eyelid skin,' said Dr Elizabeth. 

'It’s vital that you protect the eyelids and skin around the eyes with a high factor SPF and also sunglasses in order to protect the skin in this area from premature ageing.

‘Facial wrinkles start as dynamic wrinkles, which are caused by the sub-dermal movement of muscles that cause the skin above to bunch up and wrinkle. Dynamic wrinkles are temporary, lasting only as long as the muscular contraction is sustained. 

'However, dynamic wrinkles that occur repeatedly lead to permanent lasting 'static wrinkles. Muscular relaxation through anti-wrinkle treatment such as Botulinum Toxin inhibits muscle movement acting as a solution to fine lines and wrinkles. 

'This can be particularly effective to treat forehead lines, frown lines, crow’s feet or smile lines, as well as a long list of other medical issues.’

Advertisement
Wed, 20 Jul 2022 19:49:00 -0500 text/html https://www.dailymail.co.uk/femail/article-11014605/What-eyes-say-health.html
Killexams : Bausch Health Companies Inc

5.59

5.61

7,772,858.00

173.43

361.48

2,024.06

1.37

-99,999.99

P/E Excl. Extra Items (TTM)
-99,999.99

Price To Sales (TTM)
0.24

Price To Book (Quarterly)
-99,999.99

Price To Cash Flow (Per Share TTM)
1.83

Total Debt/Total Equity (Quarterly)
-99,999.99

Long Term Debt/Equity (Quarterly)
-99,999.99

Return On Investment (TTM)
-1.60

Return On Equity (TTM)
-1.34

Company Information

Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company develops, manufactures, and markets, primarily in the therapeutic areas of eye health, gastroenterology (GI), and dermatology, a range of branded, generic and branded generic pharmaceuticals, over the counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. The Company operates through five segments: Bausch + Lomb, Salix, International, Solta Medical, and Diversified Products. The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical, and Ophthalmic Pharmaceuticals products. The Salix segment consists of sales in the United States of gastrointestinal (GI) products. The Solta Medical segment consists of global sales of Solta aesthetic medical devices.

Address

2150 Saint-Elzear Blvd W
LAVAL, QC
H7L 4A8
Canada

Industry

Biotechnology & Drugs

Executive Leadership

John Paulson
Independent Chairman of the Board

Joseph C. Papa
Chief Executive Officer

Sam Eldessouky
Chief Financial Officer, Executive Vice President

Thomas J. Appio
President and Co-Head Bausch + Lomb/International

Joseph F. Gordon
President and Co-Head Bausch + Lomb/International

Christina M. Ackermann
Executive Vice President, General Counsel and Head of Commercial Operations

Richard U. De Schutter
Independent Director

Brett M. Icahn
Independent Director

Argeris N. Karabelas
Independent Director

Sarah B. Kavanagh
Independent Director

Steven D. Miller
Independent Director

Robert N. Power
Independent Director

Russel C. Robertson
Independent Director

Thomas W. Ross
Independent Director

Andrew Charles von Eschenbach
Independent Director

Amy B. Wechsler
Independent Director

Millions (USD)202120202019
Revenue843480278601
Gross Profit604057786251
Net Income-948-560-1788
Millions (USD)202120202019
Total Assets292023119933863
Total Debt226542392525895
Total Liabilities293083066432800
Millions (USD)202120202019
Cash from Operating Activities142611111501
Financing Cash Flow Items-173-107-111
Cash from Investing Activities409-261-419

Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes

Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes

Wed, 03 Aug 2022 11:59:00 -0500 en text/html https://www.reuters.com/markets/companies/BHC/
Killexams : Ophthalmic Viscoelastic Device Market Research Report Analysis by Competition, Sales, Revenue, Market Size 2022 to 2028

The MarketWatch News Department was not involved in the creation of this content.

Jul 15, 2022 (Reportmines via Comtex) -- Pre and Post Covid is covered and Report Customization is available.

As per the updated "Ophthalmic Viscoelastic Device Market" report by Report Mines, the Ophthalmic Viscoelastic Device market value was in billions in the year 2022. Furthermore, Ophthalmic Viscoelastic Device market value is expected to increase with a CAGR of (number)% from the year 2022 to 2028. In this Ophthalmic Viscoelastic Device research report, we have highlighted the various key aspects of Ophthalmic Viscoelastic Device market including market trends, sales channel, region, etc. Moreover, we have also covered an in-depth analysis on Ophthalmic Viscoelastic Device market players and they can be classified as Abbott Laboratories,ZEISS Medical,Bohus BioTech,Lifecore Biomedical,Rayner,SD Healthcare.

Get demo PDF of Ophthalmic Viscoelastic Device Market Analysis https://www.reportmines.com/enquiry/request-sample/1230327

The global Ophthalmic Viscoelastic Device market size is projected to reach multi million by 2028, in comparision to 2021, at unexpected CAGR during 2022-2028 (Ask for demo Report).

The report gives insight into segments of the market. Based on type, the market is segmented into Cohesive OVDs,Dispersive OVDs. Based on application, the market is classified into Hospitals & Clinics,Ambulatory Care Center,Others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America: United States, Canada, Europe: GermanyFrance, U.K., Italy, Russia,Asia-Pacific: China, Japan, South, India, Australia, China, Indonesia, Thailand, Malaysia, Latin America:Mexico, Brazil, Argentina, Colombia, Middle East & Africa:Turkey, Saudi, Arabia, UAE, Korea. The report is of 128 pages.

Get demo PDF of Ophthalmic Viscoelastic Device Market Analysis https://www.reportmines.com/enquiry/request-sample/1230327

The top competitors in the Ophthalmic Viscoelastic Device Market, as highlighted in the report, are:

  • Abbott Laboratories
  • ZEISS Medical
  • Bohus BioTech
  • Lifecore Biomedical
  • Rayner
  • SD Healthcare

Purchase this report https://www.reportmines.com/purchase/1230327 (Price 4900 USD for a Single-User License)

Market Segmentation

The worldwide Ophthalmic Viscoelastic Device Market is categorized on Component, Deployment, Application, and Region.

The Ophthalmic Viscoelastic Device Market Analysis by types is segmented into:

  • Cohesive OVDs
  • Dispersive OVDs

The Ophthalmic Viscoelastic Device Market Industry Research by Application is segmented into:

  • Hospitals & Clinics
  • Ambulatory Care Center
  • Others

In terms of Region, the Ophthalmic Viscoelastic Device Market Players available by Region are:

  • North America:
  • Europe:
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
  • Asia-Pacific:
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • China Taiwan
    • Indonesia
    • Thailand
    • Malaysia
  • Latin America:
    • Mexico
    • Brazil
    • Argentina Korea
    • Colombia
  • Middle East & Africa:
    • Turkey
    • Saudi
    • Arabia
    • UAE
    • Korea

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.reportmines.com/enquiry/pre-order-enquiry/1230327

Key Benefits for Industry Participants & Stakeholders

This Ophthalmic Viscoelastic Device Market Research Report focuses on numerous market influencing factors such as key driver, geographic and demographic lines, restraints, and Ophthalmic Viscoelastic Device market player opportunities.

For stakeholder and industry participants, this Ophthalmic Viscoelastic Device market analysis benefits ioj providing curated data about the Ophthalmic Viscoelastic Device market shares and size. The Ophthalmic Viscoelastic Device report also facilitates the forecasting growth aspect for the Ophthalmic Viscoelastic Device market from the year 2022 to 2028 and that too, from varied regions such as Asia, North America and Europe.

The Ophthalmic Viscoelastic Device market research report contains the following TOC:

  • Report Overview
  • Global Growth Trends
  • Competition Landscape by Key Players
  • Data by Type
  • Data by Application
  • North America Market Analysis
  • Europe Market Analysis
  • Asia-Pacific Market Analysis
  • Latin America Market Analysis
  • Middle East & Africa Market Analysis
  • Key Players Profiles Market Analysis
  • Analysts Viewpoints/Conclusions
  • Appendix

Get a demo of TOC https://www.reportmines.com/toc/1230327#tableofcontents

Highlights of The Ophthalmic Viscoelastic Device Market Report

The Ophthalmic Viscoelastic Device Market Industry Research Report contains:

  • In-depth analysis of latest Ophthalmic Viscoelastic Devicemarket trends and sales.
  • Accurate forecast on the future growth prospects of the Ophthalmic Viscoelastic Device market from 2022 to 2028.
  • Covers major struggles and problems faced by Ophthalmic Viscoelastic Devicemarket players.
  • Deep research on the Ophthalmic Viscoelastic Device market size across all regions.

Purchase this report https://www.reportmines.com/purchase/1230327 (Price 4900 USD for a Single-User License)

COVID 19 Impact Analysis

The Ophthalmic Viscoelastic Device market value experienced a downfall of about $0.0 due the global Covid-10 crisis. The report covers up all the major issues and problems that Ophthalmic Viscoelastic Devicemarket players are facing post covid. Moreover, the Ophthalmic Viscoelastic Device report covers how Covid affected the supply, sales, and value price in the Ophthalmic Viscoelastic Device market.

Get Covid-19 Impact Analysis for Ophthalmic Viscoelastic Device Market research report https://www.reportmines.com/enquiry/request-covid19/1230327

Ophthalmic Viscoelastic Device Market Size and Industry Challenges

This Ophthalmic Viscoelastic Device market research report dives deep into the various affected regions and factors due the Coviud Pnadmecic from Ophthalmic Viscoelastic Device market share , value to Ophthalmic Viscoelastic Device market problems.

Get demo PDF of Ophthalmic Viscoelastic Device Market Analysis https://www.reportmines.com/enquiry/request-sample/1230327

Reasons to Purchase the Ophthalmic Viscoelastic Device Market Report

  • The in-depth Ophthalmic Viscoelastic Device market research allows industry players to minimize the failure risk.
  • Helps in learning the upcoming Ophthalmic Viscoelastic Device market trends as well as growth prospects.
  • Region-wise Ophthalmic Viscoelastic Device market report benefits in expanding business worldwide.

Purchase this report https://www.reportmines.com/purchase/1230327 (Price 4900 USD for a Single-User License)

Contact Us:

Name: Aniket Tiwari

Email: sales@reportmines.com

Phone: USA:+1 917 267 7384 / IN:+91 777 709 3097

Website: https://www.reportmines.com/

Report Published by: ReportMines

More Reports Published By Us:

Kubernetes Solutions Market

Functional Safety Device Market

Stainless Steel Wedge Net Market

Automotive Adhesives and Sealants Market

Garage Storage Products Market

Source: QYR

Press Release Distributed by Lemon PR Wire

To view the original version on Lemon PR Wire visit Ophthalmic Viscoelastic Device Market Research Report Analysis by Competition, Sales, Revenue, Market Size 2022 to 2028

COMTEX_410215679/2788/2022-07-15T00:30:16

The MarketWatch News Department was not involved in the creation of this content.

Thu, 14 Jul 2022 16:30:00 -0500 en-US text/html https://www.marketwatch.com/press-release/ophthalmic-viscoelastic-device-market-research-report-analysis-by-competition-sales-revenue-market-size-2022-to-2028-2022-07-15
Killexams : Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

Eyenovia, Inc.

Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the CEO role

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company’s new Chief Executive Officer, effective August 1, 2022. Mr. Rowe’s appointment follows the company’s nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia’s Board of Directors, increasing the Board to nine seats following accurate appointments of Drs. Strahlman and Palanki as new independent directors, announced in July.

Eyenovia’s current Chief Executive Officer, Dr. Sean Ianchulev, previously announced that he will be transitioning to Chairman of the company’s Board.

“For the past four years, we have benefited from Michael’s diverse ophthalmic industry experience, and we believe he is the ideal candidate to shepherd Eyenovia through this exciting new chapter in the Company’s evolution,” stated Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer. “With major events anticipated in the next year, including the potential approval of MydCombi and preparation for a MicroLine New Drug Application (NDA), and significant progress being made by our strategic partners, Bausch+Lomb and Arctic Vision, agreements that Michael was instrumental in brokering, this is indeed a transformational time for our company. With his significant expertise in product development, operations, global and US commercialization, strategic planning and business development, we believe there is no one more qualified than Michael to lead our transition to a commercial-stage company. I look forward to continuing to work with him and the rest of the Eyenovia team as we work to Boost the delivery of topical ophthalmic care for patients and providers and increase the long-term value of Eyenovia for our shareholders.”

“I look forward to helping maximize the value of our proprietary Optejet dispensing technology that I believe can become the new standard across a broad range of ophthalmic uses,” stated Mr. Rowe. “With the pending resubmission of our MydCombi NDA, the upcoming completion of our VISION-2 presbyopia trial, and the commencement of our manufacturing operations in Redwood City, CA, we have made substantial progress this year, and I look forward to working with my fellow Board members and the rest of the leadership team to maintain this forward momentum.”

Mr. Rowe has served as the Company’s Chief Operating Officer since January 2021, having first joined the Company in July 2018 as Corporate Vice President. In his 30+ year career, Mr. Rowe spent 12 years at Allergan founding the health economics department, leading strategic planning and new pharmaceutical and device product commercialization for the global glaucoma franchise and founding the competitive intelligence function across the company. During this time, Mr. Rowe also served as the company’s liaison with Senju Pharmaceuticals (a current shareholder and licensee of Eyenovia) and was instrumental in the successful launch of multiple glaucoma products in the Japanese market.

More recently, Mr. Rowe was with Aerie Pharmaceuticals, Inc. where he was pivotal in the commercialization of their glaucoma franchise. Mr. Rowe has also held leadership roles at Bayer Healthcare Pharmaceuticals Inc. and Pfizer, Inc.

About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, genuine outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

Wed, 27 Jul 2022 00:00:00 -0500 en-US text/html https://finance.yahoo.com/news/eyenovia-announces-appointment-ophthalmic-industry-120000648.html
Killexams : IRIX.O - IRIDEX Corporation | Stock Price & Latest News | Reuters

3.12

3.19

80,039.00

0.73

15.89

49.57

-6.12

-99,999.99

P/E Excl. Extra Items (TTM)
-99,999.99

Price To Sales (TTM)
0.90

Price To Book (Quarterly)
2.32

Price To Cash Flow (Per Share TTM)
-99,999.99

Total Debt/Total Equity (Quarterly)
0.00

Long Term Debt/Equity (Quarterly)
0.00

Return On Investment (TTM)
-15.52

Return On Equity (TTM)
-11.49

Company Information

Iridex Corporation is an ophthalmic medical technology company, which is focused on the development and commercialization of products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. The Company’s laser consoles products consist of Glaucoma, which includes Cyclo G6 laser and delivery devices used for the treatment of glaucoma; Medical Retina product, which includes IQ 532 Laser and IQ 577 Laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases, and its PASCAL Synthesis Photocoagulator for the treatment of retinal diseases; Surgical Retina, which includes OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. Its laser probes products consist of Glaucoma, which include MicroPulse P3 Probe, G-Probe and G-Probe Illuminate, and Surgical Retina probes, which include EndoProbe family of products used in vitrectomy procedures.

Address

1212 Terra Bella Ave
MOUNTAIN VIEW, CA
94043-1824
United States

Industry

Medical Equipment & Supplies

Executive Leadership

Scott A. Shuda
Independent Chairman of the Board

David I. Bruce
President, Chief Executive Officer, Director

Fuad Ahmad
Interim Chief Financial Officer

Patrick Mercer
Chief Operating Officer

Beverly A. Huss
Director

Nandini Devi
Independent Director

Robert Earle Grove
Independent Director

Kenneth E. Ludlum
Independent Director

Millions (USD)202220212019
Revenue53.90336.34743.447
Gross Profit22.83115.55817.939
Net Income-5.225-6.329-8.813
Millions (USD)202220212019
Total Assets48.68727.96934.813
Total Debt02.4970
Total Liabilities25.38810.60312.108
Millions (USD)202220212019
Cash from Operating Activities8.217-3.237-7.913
Financing Cash Flow Items-0.629-0.03-0.156
Cash from Investing Activities-5.556-0.093-0.509

Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes

Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes

Wed, 03 Aug 2022 11:59:00 -0500 en text/html https://www.reuters.com/markets/companies/IRIX.O
Killexams : Global Ophthalmic Instrumentation Market 2022 - Prime Factors, Segments Insights, Technology Advancement Outlook, and Growth Forecast Up to 2028

The MarketWatch News Department was not involved in the creation of this content.

Jul 18, 2022 (CDN Newswire via Comtex) -- The report named Global Ophthalmic Instrumentation Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 presents this market’s past performance analysis, latest market performance estimation for the current year, and provides the prediction for 2022 to 2028 time-period. The report offers a thorough market investigation and comprehensively analyzes all aspects of this industry. The report is an arrangement of itemized market outline dependent on sorts, application, key contenders, and regions. It gives a forecast that is supposed to drive or restrain the global Ophthalmic Instrumentation market.

The report provides insights on market sizing, industry overviews, forecasting, and identification of major trends and significant market participants. We help consumers in recognizing new market opportunities with precise and reliable information. It focuses on each player and their sales by unit by the brand make this report unique in the global Ophthalmic Instrumentation industry. The performance of each player in all industry verticals is analyzed in the report.

DOWNLOAD FREE demo REPORT: https://www.marketsandresearch.biz/sample-request/283964

The research methodology behind this report consists of secondary research, primary research, company share analysis, model (including demographic data, macroeconomic indicators, and industry indicators i.e. expenditure, infrastructure, sector growth, and facilities, etc), research limitations, and revenue-based modeling.

This comprehensive study includes an overview of the various aspects of the global Ophthalmic Instrumentation industry from an industry perspective, including trends in the current market and forecast period in advance. Further, the report has analyzed the market concerning the regional landscape which incorporates extensive details about the types and application spectrums of this business.

Key competitors included in the market are:

  • Alcon
  • Bausch + Lomb
  • Carl Zeiss Meditec
  • Johnson & Johnson
  • Ellex Medical Lasers
  • Hoya
  • Iridex
  • Lumenis
  • Nidek
  • Staar Surgical
  • Topcon
  • Ziemer Ophthalmic Systems

On the basis of product, this report displays:

  • Cataracts
  • Refractive Glaucoma
  • Vitreoretinal Surgical Microscope

On the basis of the end users/applications, this report focuses on:

  • Hospital
  • Specialty Clinic

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/283964/global-ophthalmic-instrumentation-market-2022-by-manufacturers-regions-type-and-application-forecast-to-2028

Based on regions, the market is classified into:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The report provides a detailed analysis of the countries in the region, covering the key challenges, competitive landscape, and demographic analysis, that can help companies gain insight into the country-specific variations. This global Ophthalmic Instrumentation market research report covers the new survey on market, which helps the marketers to find the latest market dynamics, a new development in the market and the industry.

Customization of the Report:

This report can be customized to meet the client's requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact Us
Mark Stone
Head of Business Development
Phone: +1-201-465-4211
Email:sales@marketsandresearch.biz
Web:www.marketsandresearch.biz

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

COMTEX_410490030/2657/2022-07-18T23:39:27

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Mon, 18 Jul 2022 18:01:00 -0500 en-US text/html https://www.marketwatch.com/press-release/global-ophthalmic-instrumentation-market-2022---prime-factors-segments-insights-technology-advancement-outlook-and-growth-forecast-up-to-2028-2022-07-18
Killexams : Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif., July 13, 2022--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 3, 2022.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005101/en/

Contacts

Chris Lewis
Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com

Tue, 12 Jul 2022 23:01:00 -0500 en-US text/html https://www.yahoo.com/now/glaukos-release-second-quarter-2022-110000323.html
OCS exam dump and training guide direct download
Training Exams List